Lineage Cell Therapeutics Inc. [AMEX: LCTX] surged by $0.31 during the normal trading session on Tuesday and reaching a high of $2.58 during the day while it closed the day at $2.48. The company report on December 28, 2020 that Lineage Cell Therapeutics Provides End of Year Shareholder Letter.
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, provided a year-end review and an outline of its plans for 2021.
To Our Shareholders,.
Lineage Cell Therapeutics Inc. stock has also gained 20.98% of its value over the past 7 days. However, LCTX stock has inclined by 90.77% in the 3 months of the year. Over the past six months meanwhile, it has gained 191.76% and gained 40.91% year-on date.
The market cap for LCTX stock reached $372.00 million, with 149.97 million shares outstanding and 142.42 million shares in the current float. Compared to the average trading volume of 1.14M shares, LCTX reached a trading volume of 3515491 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Lineage Cell Therapeutics Inc. [LCTX]:
The Average True Range (ATR) for Lineage Cell Therapeutics Inc. is set at 0.16, with the Price to Sales ratio for LCTX stock in the period of the last 12 months amounting to 137.78. The Price to Book ratio for the last quarter was 4.07, with the Price to Cash per share for the same quarter was set at 0.25.
LCTX stock trade performance evaluation
Lineage Cell Therapeutics Inc. [LCTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.98. With this latest performance, LCTX shares gained by 36.26% in over the last four-week period, additionally plugging by 191.76% over the last 6 months – not to mention a rise of 206.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LCTX stock in for the last two-week period is set at 81.19, with the RSI for the last a single of trading hit 85.63, and the three-weeks RSI is set at 77.60 for Lineage Cell Therapeutics Inc. [LCTX]. The present Moving Average for the last 50 days of trading for this stock 1.67, while it was recorded at 2.19 for the last single week of trading, and 1.11 for the last 200 days.
Lineage Cell Therapeutics Inc. [LCTX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Lineage Cell Therapeutics Inc. [LCTX] shares currently have an operating margin of -2423.07 and a Gross Margin at -130.85. Lineage Cell Therapeutics Inc.’s Net Margin is presently recorded at -792.22.
Return on Total Capital for LCTX is now -33.96, given the latest momentum, and Return on Invested Capital for the company is -11.01. Return on Equity for this stock declined to -11.32, with Return on Assets sitting at -10.31. When it comes to the capital structure of this company, Lineage Cell Therapeutics Inc. [LCTX] has a Total Debt to Total Equity ratio set at 4.58. Additionally, LCTX Total Debt to Total Capital is recorded at 4.37, with Total Debt to Total Assets ending up at 4.12. Long-Term Debt to Equity for the company is recorded at 3.49, with the Long-Term Debt to Total Capital now at 3.34.
Reflecting on the efficiency of the workforce at the company, Lineage Cell Therapeutics Inc. [LCTX] managed to generate an average of -$212,891 per employee. Receivables Turnover for the company is 0.10 with a Total Asset Turnover recorded at a value of 0.01.Lineage Cell Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.10 and a Current Ratio set at 5.10.
Earnings per share (EPS) analysis for Lineage Cell Therapeutics Inc. [LCTX] stock
With the latest financial reports released by the company, Lineage Cell Therapeutics Inc. posted -0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.05/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 40.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LCTX.
Lineage Cell Therapeutics Inc. [LCTX]: Insider Ownership positions
There are presently around $133 million, or 35.80% of LCTX stock, in the hands of institutional investors. The top three institutional holders of LCTX stocks are: BROADWOOD CAPITAL INC with ownership of 34,005,379, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 5,228,057 shares of the stock with an approximate value of $12.97 million in LCTX stocks shares; and DEFENDER CAPITAL, LLC., currently with $12.52 million in LCTX stock with ownership of nearly 8.667% of the company’s market capitalization.
Positions in Lineage Cell Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 15 institutional holders increased their position in Lineage Cell Therapeutics Inc. [AMEX:LCTX] by around 1,077,702 shares. Additionally, 45 investors decreased positions by around 3,287,594 shares, while 36 investors held positions by with 49,152,150 shares. The mentioned changes placed institutional holdings at 53,517,446 shares, according to the latest SEC report filing. LCTX stock had 4 new institutional investments in for a total of 103,916 shares, while 21 institutional investors sold positions of 1,840,382 shares during the same period.